While these medicationsincluding semaglutide (Ozempic, Wegovy, Rybelsus) and liraglutide (Victoza, Saxenda)are FDA-approved only for metabolic conditions, emerging research explores whether their anti-inflammatory properties and effects on brain glucose metabolism might slow cognitive decline
Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as an Add-on to Metformin, Thiazolidinediones, or Both, in Patients With Type 2 Diabetes (SUSTAIN 2): A 56-Week, Double-Blind, Phase 3a, Randomised Trial
18F-labeled PEGylated exendin-4 imaging noninvasively differentiates insulinoma from an accessory spleen: the first case report of [18F]FB(ePEG12)12-exendin-4 positron emission tomography/computed tomography for insulinoma
Underlying Health Conditions Are Slowing Results Certain medical conditions can make weight loss more challenging